Summary

This article discusses the evidence from clinical trials addressing the reduction of cardiovascular (CV) risk with antihyperglycemic drugs. Specific trials include the UKPDS, ACCORD, RECORD, NAVIGATOR, and ORIGIN trials, as well as a number of ongoing clinical trials examining the CV safety of dipeptidyl peptidase-4 inhibitors.